Brooklyn ImmunoTherapeutics Inc. (AMEX:BTX) went down by -5.68% from its latest closing price compared to the recent 1-year high of $80.67. The company’s stock price has collected 1.10% of gains in the last five trading sessions. Press Release reported on 09/13/21 that Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET
Is It Worth Investing in Brooklyn ImmunoTherapeutics Inc. (AMEX :BTX) Right Now?
Plus, the 36-month beta value for BTX is at 4.86. Opinions of the stock are interesting as 0 analysts out of 1 who provided ratings for Brooklyn ImmunoTherapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $11.00. BTX currently public float of 24.24M and currently shorts hold a 4.43% ratio of that float. Today, the average trading volume of BTX was 1.94M shares.
BTX’s Market Performance
BTX stocks went up by 1.10% for the week, with a monthly jump of 7.55% and a quarterly performance of -19.79%, while its annual performance rate touched 249.71%. The volatility ratio for the week stands at 11.39% while the volatility levels for the past 30 days are set at 9.11% for Brooklyn ImmunoTherapeutics Inc.. The simple moving average for the period of the last 20 days is 7.34% for BTX stocks with a simple moving average of 1.35% for the last 200 days.
BTX Trading at 2.21% from the 50-Day Moving Average
After a stumble in the market that brought BTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.17% of loss for the given period.
Volatility was left at 9.11%, however, over the last 30 days, the volatility rate increased by 11.39%, as shares surge +11.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.06% lower at present.
During the last 5 trading sessions, BTX rose by +1.10%, in comparison to the 20-day moving average, which settled at $11.20. In addition, Brooklyn ImmunoTherapeutics Inc. saw 166.96% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BTX starting from DENNY GEORGE P III, who purchase 1 shares at the price of $11.99 back on Jul 14. After this action, DENNY GEORGE P III now owns 3 shares of Brooklyn ImmunoTherapeutics Inc., valued at $12 using the latest closing price.
DENNY GEORGE P III, the 10% Owner of Brooklyn ImmunoTherapeutics Inc., purchase 1 shares at $14.11 during a trade that took place back on Jul 09, which means that DENNY GEORGE P III is holding 2 shares at $14 based on the most recent closing price.
Stock Fundamentals for BTX
Current profitability levels for the company are sitting at:
- -93.09 for the present operating margin
- +46.41 for the gross margin
The net margin for Brooklyn ImmunoTherapeutics Inc. stands at -76.12. The total capital return value is set at -76.52, while invested capital returns managed to touch -94.09. Equity return is now at value -361.00, with -123.00 for asset returns.
Based on Brooklyn ImmunoTherapeutics Inc. (BTX), the company’s capital structure generated 245.59 points at debt to equity in total, while total debt to capital is 71.06. Total debt to assets is 49.83, with long-term debt to equity ratio resting at 62.59. Finally, the long-term debt to capital ratio is 18.09.
When we switch over and look at the enterprise to sales, we see a ratio of 1.36, with the company’s debt to enterprise value settled at 0.27. The receivables turnover for the company is 8.85 and the total asset turnover is 0.60. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.73.